Post‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A-Reference-Cited by-同舟云学术

Post‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A

Published:2021-09-25 Issue:1 Volume:28 Page:27-35
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Tiede Andreas¹^ORCID,Hampton Kingsley²^ORCID,Jiménez‐Yuste Victor³^ORCID,Young Guy⁴^ORCID,Benchikh el Fegoun Soraya⁵^ORCID,Chowdary Pratima⁶^ORCID

Affiliation:

1. Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation Hannover Medical School Hanover Germany

2. Department of Cardiovascular Science University of Sheffield Sheffield UK

3. Department of Hematology La Paz University Hospital‐IdiPaz Autónoma University Madrid Spain

4. Hemostasis and Thrombosis Center, Cancer and Blood Disorders Institute, Children's Hospital Los Angeles University of Southern California Keck School of Medicine Los Angeles California USA

5. Global Medical Affairs Biopharm Novo Nordisk Health Care AG Zürich Switzerland

6. Katharine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital London UK

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14409

Reference22 articles.

1. WFH Guidelines for the Management of Hemophilia, 3rd edition

2. Extended half-life recombinant products in haemophilia clinical practice – Expectations, opportunities and challenges

3. Elocta®Summary of product characteristics.https://www.ema.europa.eu/en/documents/product‐information/elocta‐epar‐product‐information_en.pdf

4. Adynovi®Summary of product characteristics.https://www.ema.europa.eu/en/documents/product‐information/adynovi‐epar‐product‐information_en.pdf

5. Jivi®. Summary of product characteristics.https://www.ema.europa.eu/en/documents/product‐information/jivi‐epar‐product‐information_en.pdf